Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats

Molecular and Cellular Biochemistry

Volumn 304, Issue 1-2, 2007, Pages 35-43

  Zhu, Wei Wei ^a   Liu, Xue Ping ^a   Wu, Nan ^a   Zhao, Ting Ting ^a   Zhao, Yong ^a   Zhang, Jie ^a   Shao, Jian Hua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Advanced glycosylation end products; Endothelial function (endothelium derived relaxing factor); Hypertension; Losartan; Vascular remodeling

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ENDOTHELIN 1; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MALONALDEHYDE; MESSENGER RNA; NITRIC OXIDE; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOFLUORESCENCE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT DURATION; WISTAR KYOTO RAT;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; BODY WEIGHT; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART RATE; HYPERTENSION; LOSARTAN; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, IMMUNOLOGIC; REGENERATION; RNA, MESSENGER; VASCULAR DISEASES;

RATTUS;

EID: 34648828860     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-007-9483-9     Document Type: Article

References (37)

1. Sell DR, Primc M, Schafer IA, Kovach M, Weiss MA, Monnier VM (1998) Cell-associated pentosidine as a marker of aging in human diploid cells in vitro and in vivo. Mech Ageing Dev 105:221-240
2. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T (2003) Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23:129-134
3. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 6:351-358
4. Seki N, Hashimoto N, Sano H, Horiuchi S, Yagui K, Makino H, Saito Y (2003) Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism 52:1558-1563
5. Aso Y, Inukai T, Tayama K, Takemura Y (2000) Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37:87-92
6. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S (2003) Pigment epithelium-derived factor prevents advanced glycation endproducts-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 46:284-287
7. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y (2004) Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 19:3012-3020
8. Mariee AD, Al-Shabanah O (2006) Protective ability and binding affinity of captopril towards serum albumin in an in vitro glycation model of diabetes mellitus. J Pharm Biomed Anal 41:571-575
9. Toblli JE, Stella I, Mazza ON, Ferder L, Inserra F (2004) Different effect of losartan and amlodipine on penile structures in male spontaneously hypertensive rats. Am J Nephrol 24:614-623
10. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358
11. Sun Y, Oberley LW, Li Y (1998) A simple method for clinical assay of superoxide dismutase. Clin Chem 34:497-500
12. Kum-Tatt L, Tan IK (1974) A new colorimetric method for the determination of glutathione in erythrocytes. Clin Chim Acta 53:153-161
13. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite and nitrate in biological fluids. Anal Biochem 126:131-138
14. Siegl PS (1993) Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens 11:S19-S22
15. Cuspidi C, Meani S, Valerio C, Fusi V, Sala C, Maisaidi M, Zanchetti A (2006) Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients. Blood Press 15:107-115
16. De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A (2002) Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 16:133-140
17. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M (2005) Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 28:593-600
18. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A (1999) Advanced glycation end-product levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 25:380-383
19. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C (1997) Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181
20. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML (1993) Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232
21. Wu L, Juurlink BH (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809-814
22. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K (2000) Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 86:E50-E54
23. Thornalley PJ (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44:1013-1023
24. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D (1996) RAGE: A novel cellular receptor for advanced glycation end products. Diabetes 45:S77-S80
25. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y (2003) Central role of RAGE dependent neointimal expansion in arterial restenosis. J Clin Invest 111:959-972
26. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2003) The receptor RAGE as progression factor amplifying arachidonate dependent inflammatory and proteolytic response in human atherosclerotic plaques, role of glycemic control. Circulation 108:1070-1077
27. Kanauchi M, Tsujimoto N, Hashimoto T (2001) Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 24:1620-1623
28. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidative stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694
29. Hector Polizio A, Pena C (2005) Effects of angiotensin II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues. Regul Pept 128:1-5
30. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, Imaizumi T (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70:137-141
31. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM (2005) Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 16:2976-2984
32. Li N, Karin M (1999) Is NF-kappaB the sensor of oxidative stress? FASEB J 13:1137-1143
33. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897
34. Wautier JL, Guillausseau PJ (2001) Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27:535-542
35. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP (2000) Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49:1561-1570
36. Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM (2004) Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. Kidney Int 65:1664-1675
37. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced glycosylation end products is induced by the glycation product themselves and TNF-alpha through nuclear factor kappa B and by 17-beta-estradiol through Sp1 in human vascular endothelial cells. J Biol Chem 275:25781-25790